A combination therapy targeting endoglin and VEGF-A prevents subretinal fibro-neovascularization caused by induced müller cell disruption

Shen W., Lee S.-R., Yam M., Zhu L., Zhang T., Pye V., Mathai A.E., Shibagaki K., Zhang J.-Z., Matsugi T., Gillies M.C.

2018
Investigative Ophthalmology and Visual Science

View publication

Therapeutic Area

Back of the eye (BOTE)
Categories

Preclinical development

Affiliations

The University of Sydney, Save Sight Institute Discipline of Ophthalmology, Sydney Medical School, Sydney, NSW, Australia; Department of Non-Clinical Research, Global R&D, Santen Pharmaceutical Co. Ltd., Nara, Japan

Related Publications

Cutamesine (SA4503) Protects Retinal Ganglion Cells in an Ocular Hypertension Model of Glaucoma Determined Using Detection of Apoptosing Retinal Cells Technology and RBPMS Cell Marker

Sharif N.A., Takashi O., Taniguchi T., Sasaoka M., Guo L., Choi S., Luong V., Cordeiro M.F.

Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase 2/3 ORANGE Study

Ohno-Matsui K., Igarashi-Yokoi T., Migita Y., Yamakawa Y. on behalf of the ORANGE study investigators

Epidemiology and burden of mild/moderate versus high myopia in Germany: A claims data analysis

Garcia TB, Kossack N, Pignot M, Dagher M, Schuster AK, Wielink KS.

View all Back of the eye (BOTE) publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022